Klivira
Request demo

Automating eMDs Dupixent Prior Authorization Workflows

Klivira optimizes the complex process of **eMDs Dupixent prior authorization**, integrating directly with CGM eMDs to automate data submission and accelerate approvals for this critical IL-4/IL-13 inhibitor.

For ambulatory practices leveraging CGM eMDs, managing prior authorizations for high-volume specialty medications like Dupixent presents significant operational challenges. The manual retrieval of clinical documentation and submission via payer portals or X12 278 transactions often leads to delays and administrative burden. Klivira addresses these bottlenecks by providing a purpose-built automation layer.

The eMDs Workflow for Dupixent Prior Authorization

Within CGM eMDs, ordering Dupixent (dupilumab) typically initiates a prior authorization requirement due to its specialty drug status. The workflow often involves order entry, subsequent identification of PA necessity, and then manual or semi-automated routing to an ePA partner or specialty pharmacy, frequently via an external portal or fax. This process, spanning both pharmacy and medical benefits, requires meticulous data extraction.

Navigating Pharmacy vs. Medical Benefit for Dupixent in eMDs

Dupixent, as an injectable biologic, can fall under either the pharmacy benefit (e.g., self-administered subcutaneous injection dispensed by a specialty pharmacy) or the medical benefit (e.g., administered in-office). Klivira's integration with CGM eMDs is designed to identify the correct benefit pathway, ensuring appropriate documentation and submission protocols are followed, whether it's an NCPDP SCRIPT ePA or a medical benefit X12 278 transaction.

Klivira's Data Extraction for Dupixent PAs from CGM eMDs

Klivira leverages CGM APIs to programmatically access relevant patient data points within eMDs. For Dupixent, this includes extracting specific clinical information from progress notes, problem lists, medication histories, and diagnostic results to fulfill payer-specific criteria for conditions such as atopic dermatitis, asthma, or eosinophilic esophagitis.

Key Clinical Data Points Klivira Pulls from eMDs for Dupixent PAs

  • Diagnosis codes (ICD-10) from the problem list (e.g., L20.85 for moderate-to-severe atopic dermatitis).
  • Documentation of prior failed therapies or contraindications to standard treatments.
  • Severity assessments (e.g., Eczema Area and Severity Index (EASI) scores, FEV1 for asthma).
  • Biomarker levels (e.g., eosinophil counts, IgE levels).
  • Patient weight and age for dosing considerations.
  • Concomitant medication history and allergies.

Streamlining Specialty Pharmacy Routing with eMDs Integration

Once a Dupixent prior authorization is approved, Klivira can facilitate the electronic routing of the prescription and approval documentation to the designated specialty pharmacy. This eliminates manual faxes or phone calls, ensuring a seamless transition from approval to medication fulfillment, directly interfacing with the eMDs order.

Achieving Efficiency and Compliance with Klivira and eMDs

By automating the data retrieval and submission for Dupixent PAs, Klivira reduces the administrative burden on your staff, minimizes potential for human error, and accelerates patient access to critical therapies. This integration with CGM eMDs helps maintain compliance with payer requirements and supports efficient revenue cycle management within ambulatory practices.

Frequently asked questions

How does Klivira integrate with CGM eMDs for Dupixent prior authorizations?

Klivira integrates with CGM eMDs through its robust CGM APIs, allowing for secure, programmatic access to patient clinical data. This connection enables automated extraction of necessary documentation to support Dupixent prior authorization requests, directly from the EMR.

Can Klivira differentiate between Dupixent PAs for pharmacy benefit versus medical benefit within eMDs?

Yes, Klivira is engineered to identify whether Dupixent is being requested under the pharmacy or medical benefit. This distinction is crucial for initiating the correct prior authorization pathway, whether it involves an NCPDP SCRIPT ePA for pharmacy claims or an X12 278 transaction for medical claims, all while pulling relevant data from eMDs.

What specific Dupixent indications does Klivira support for PA automation with eMDs?

Klivira supports Dupixent prior authorizations across all its approved indications, including atopic dermatitis, asthma, eosinophilic esophagitis, and chronic rhinosinusitis with nasal polyps. Our system is configured to extract the specific clinical evidence required by payers for each indication from your eMDs records.

Does Klivira's eMDs integration support Da Vinci PAS for Dupixent PAs?

Klivira actively supports industry standards like Da Vinci PAS (Prior Authorization Support) where available from payers and EMRs. Our integration with CGM eMDs is designed to leverage these standards for electronic prior authorization submission, aiming to streamline the Dupixent PA process further.

How does Klivira ensure data security and HIPAA compliance when pulling PHI from eMDs for Dupixent PAs?

Klivira is built with a strong focus on data security and HIPAA compliance. All data exchanges with CGM eMDs occur over secure, encrypted channels. We adhere to strict access controls and data handling protocols to protect PHI throughout the prior authorization process, ensuring compliance with all applicable regulations.

Related coverage

Other emds prior auth coverage

Ready to automate prior auth for this integration?

See how Klivira automates prior authorizations for your team.

Request a demo